Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Related Parties

Related Parties	3 Months Ended
Mar. 31, 2023
Related Parties
Related Parties	7Related Parties The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design and planning, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member is the Company’s Chief Medical Officer (“CMO”). The Company will continue to contract the services of the CMO’s spouse through Gendreau to perform certain activities in connection with the Company’s ongoing clinical development of its product candidates. During the three months ended March 31, 2023 and 2022, the Company paid Gendreau $39,973 and $85,548, respectively, and had accounts payable of $11,165 and $21,000 to Gendreau as of March 31, 2023 and December 31, 2022, respectively.

Related Parties

3 Months Ended

Mar. 31, 2023

7Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design and planning, implementation and execution of contracted activities with the clinical

research organization. Gendreau’s managing member is the Company’s Chief Medical Officer (“CMO”). The Company will continue to contract the services of the CMO’s spouse through Gendreau to perform certain activities in connection with the Company’s ongoing clinical development of its product candidates. During the three months ended March 31, 2023 and 2022, the Company paid Gendreau $39,973 and $85,548, respectively, and had accounts payable of $11,165 and $21,000 to Gendreau as of March 31, 2023 and December 31, 2022, respectively.